|
시장보고서
상품코드
2008009
전임상 자산 시장 : 서비스별, 모델 유형별, 최종사용자별, 지역별Preclinical Assets Market, By Service, By Model type, By End user, By Geography |
||||||
가격
※ 부가세 별도
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
전임상 자산 시장은 2026년에 68억 달러로 추정되고 있으며, 2033년까지 92억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 8.6%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 68억 달러 |
| 실적 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 8.60% | 2033년 시장 규모 예측 : | 92억 달러 |
전임상 자산에는 바이오 분석, DMPK(약물대사 및 약동학) 시험 등 다양한 유형의 서비스가 포함됩니다. GLP(적정실험실관리기준) 및 비 GLP 기반 in vitro 및 in vivo 분석, 독성시험, 화합물 관리 프로세스, R&D(연구개발), 위탁합성, 비대칭합성, 기타(스케일업, cGMP(현행 적정제조기준), 안전약리) 등 다양한 유형의 서비스로 구성되어 있습니다. 전임상 자산에는 환자 유래 유기체(PDO) 모델과 환자 유래 이종이식 모델의 두 가지 모델이 있습니다.
시장 역학
주요 시장 기업의 전임상 시험 서비스 출시가 증가함에 따라 예측 기간 중 글로벌 전임상 자산 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2020년 7월, 화장품 기업 스킨옵스(Skinobs)는 생체내 유효성 시험의 360도 관점을 제공하는 독립적인 툴인 새로운 전임상 시험 플랫폼 '스킨옵스(skinobs)'의 출시를 발표했습니다. 이 플랫폼을 통해 사용자는 다음과 같은 다양한 기준에 따라 시험 방법을 식별하고 선택할 수 있습니다.
- 시험 범주: 분석 시험, 성분 및 용기 상호작용 시험, 생태독성 및 생분해성 시험, 안전성 시험, UV(자외선) 시험 등이 포함됩니다.
- 효능: 안티에이징, 안티에이징, 안티폴루션 등이 포함됩니다.
- 시험 지원: 세포배양, 3D 피부 모델 등이 포함됩니다.
마찬가지로 2021년 12월, 소프트웨어 기업 시로나 메디컬(Sirona Medical)은 2021년 북미방사선학회(RSNA) 연례총회에서 임상에서 새로운 인공지능(AI) 애플리케이션의 활용을 최적화하는 클라우드 네이티브 방사선 의학 운영 체제(RadOS)를 발표했습니다. (RadOS)의 출시를 발표했습니다. 이 플랫폼은 기술과 인공지능의 융합을 기반으로 임상 현장에서 의사의 판단력을 강화하는 데 도움이 되는 플랫폼입니다.
본 조사의 주요 특징:
- 이 보고서는 2025년을 기준연도로 하여 2026-2033년의 예측 기간 중 전 세계 임상 전 자산 시장, 시장 규모, 연평균 성장률(CAGR)에 대한 상세한 분석을 전해드립니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하고 있는 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 회사 개요, 재무 실적, 제품 포트폴리오, 사업 지역, 유통 전략, 주요 개발 및 전략과 같은 매개 변수를 기반으로 세계의 전임상 자산 시장의 주요 기업 개요을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 정부 주도 구상, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 세계의 전임상 자산 시장 보고서는 투자자, 제품 제조업체, 유통업체, 공급업체, 연구 및 컨설팅 회사, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 전임상 자산 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 전임상 자산 시장 : 서비스별, 2026-2033년
제5장 세계의 전임상 자산 시장 : 모델 유형별, 2026-2033년
제6장 세계의 전임상 자산 시장 : 최종사용자별, 2026-2033년
제7장 세계의 전임상 자산 시장 : 지역별, 2026-2033년
제8장 경쟁 구도
제9장 섹션
KSAPreclinical Assets Market is estimated to be valued at USD 6.8 Bn in 2026 and is expected to reach USD 9.2 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 6.8 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.60% | 2033 Value Projection: | USD 9.2 Bn |
Preclinical assets consist of various types of services such as Bioanalysis and DMPK (Drug Metabolism and pharmacokinetics) studies, which are further sub segmented into in vitro and in vivo analysis, toxicology testing, which are based on GLP and non GLP (Good Laboratory Practices), compound management process R&D (Research and development), custom synthesis, asymmetric synthesis, and others (Scale-up, cGMP (current good manufacturing practices), safety pharmacology). Preclinical assets have two types of models, patient derived organoid (PDO) model and patient derived xenograft model.
Market Dynamics
Increasing number of service launch in preclinical testing by the key market players is expected to drive growth of the global preclinical assets market during the forecast period. For instance, in July 2020, Skinobs, a cosmetic company, announced the launch of a new preclinical testing platform skinobs, an independent tool which provides a 360-degree vision of in vivo efficacy testing. This platform enables users to identify and select the testing methods depending on various criteria such as
- Test Category: which include analytical tests, content-contenair interaction, ecotoxicity and biodegradability tests, safety tests, UV (Ultra Violet ) tests, etc.
- Claim: which include anti-ageing, anti-pollution, etc.
- Test support: which include cell cultures, 3D skin models, etc.
Similarly, in December 2021, Sirona Medical, a software company, announced the launch of its cloud-native radiology operating system (RadOS) optimizing the use of novel AI (Artificial Intelligence) applications in clinical practice at the 2021 Annual Meeting for Radiological Society of North America (RSNA). The platform was based on the combination of technology and artificial intelligence, which would help augment the intelligence of the physician in clinical practices.
Key features of the study:
- This report provides an in-depth analysis of the global preclinical assets market, market size (USD Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global preclinical assets market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Eurofins Scientific, ICON plc, WuXi AppTec, Viroclinics Xplore, Medpace, Inc., Charles River Laboratories., Pharmatest Services, PPD Inc., SGS SA (SGS), Intertek Group plc, Labcorp Drug Development, Laboratory Corporation of America, Inc., Crown Bioscience, Comparative Biosciences, Inc., TCG Lifesciences Private Limited., Shanghai Medicilon Inc., Domainex, Absorption Systems, AmplifyBio, and IQVIA
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global preclinical assets market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preclinical assets market
Market Segmentation
- By Service
- Bioanalysis and DMPK studies
- In vitro
- In-vivo
- Toxicology Testing
- GLP
- Non-GLP
- compound management
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis & Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- By Model type
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- By End user
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Eurofins Scientific
- ICON plc
- WuXi AppTec
- Viroclinics Xplore
- Medpace, Inc.
- Charles River Laboratories.
- Pharmatest Services
- PPD Inc.
- SGS SA (SGS)
- Intertek Group plc
- Labcorp Drug Development
- Laboratory Corporation of America, Inc.
- Crown Bioscience
- Comparative Biosciences, Inc.
- TCG Lifesciences Private Limited.
- Shanghai Medicilon Inc.
- Domainex
- Absorption Systems
- AmplifyBio
- IQVIA
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Service
- Market Snapshot, By Model Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Technological Advancements
- Regulatory Landscape
- PEST Analysis
4. Global Preclinical Assets Market, By Service, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Bioanalysis and DMPK studies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- In vitro
- In-vivo
- Toxicology Testing
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- GLP
- Non-GLP
- Compound Management
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up and cGMP)
- Safety Pharmacology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others (Chemistry, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Preclinical Assets Market, By Model Type, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Patient Derived Organoid (PDO) Model
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Patient derived xenograft model
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Preclinical Assets Market, By End User, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Biopharmaceutical Companies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Government Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others (Academic and Research institutes)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Preclinical Assets Market, By Region, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026-2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Company Profile
- Eurofins Scientific
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- ICON plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- WuXi AppTec
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Viroclinics Xplore
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Medpace, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Charles River Laboratories.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pharmatest Services
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PPD Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- SGS SA (SGS)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Intertek Group plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Labcorp Drug Development
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Laboratory Corporation of America, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Crown Bioscience
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Comparative Biosciences, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- TCG Lifesciences Private Limited.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Shanghai Medicilon Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Domainex
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Absorption Systems
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AmplifyBio
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- IQVIA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
샘플 요청 목록